QR 010

Drug Profile

QR 010

Alternative Names: Antisense oligonucleotide targeting the F508delta mutation of CFTR - ProQR Therapeutics; QR 10; QR-010

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ProQR Therapeutics
  • Class Oligoribonucleotides
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 16 Aug 2017 ProQR completes enrolment in its phase Ib trial for Cystic fibrosis in USA, Belgium, Canada, Czech Republic, Denmark, France, Italy, Germany and the United Kingdom
  • 03 Apr 2017 ProQR has patent protection for QR 010 in USA and European Union
  • 28 Feb 2017 ProQR Therapeutics plans a phase II trial for cystic fibrosis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top